Helena Linardou: Pivotal Paper on Tarlatamab in 2nd Line SCLC by Giannis Mountzios and Colleagues
Helena Linardou, Director of the 4th Oncology Department and the Comprehensive Clinical Trials Center at Metropolitan Hospital, shared a post on LinkedIn:
“A significant milestone for oncology and a moment of exceptional pride!
The NEJM has just published a pivotal paper on Tarlatamab in second-line small-cell lung cancer (SCLC) – with my dear friend and colleague Giannis Mountzios as first author.
This achievement marks:
• A breakthrough for patients with few treatment options,
• A moment of recognition for Greek oncology on the global research stage, and
• A personal triumph for someone whose dedication to science and patient care is second to none.Huge congratulations, Giannis Mountzios, your work continues to push the field forward and inspire so many of us.
Sooo happy and super proud of you!!”
Title: Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Authors: Giannis Mountzios, Longhua Sun, Byoung Chul Cho, Umut Demirci, Sofia Baka, Mahmut Gümüş, Antonio Lugini, Bo Zhu, Yan Yu, Ippokratis Korantzis, Ji-Youn Han, Tudor-Eliade Ciuleanu, Myung-Ju Ahn, Pedro Rocha, Julien Mazières, Sally C.M. Lau, Martin Schuler, Fiona Blackhall, Tatsuya Yoshida, Taofeek K. Owonikoko, Luis Paz-Ares, Tony Jiang, Ali Hamidi, Diana Gauto, Gonzalo Recondo, Charles M. Rudin
Read OncoDaily’s Special Articles:
Tarlatamab (Imdelltra): What Patients Need to Know About
Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages, Expectations, and More
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023